JP2008501701A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501701A5
JP2008501701A5 JP2007515574A JP2007515574A JP2008501701A5 JP 2008501701 A5 JP2008501701 A5 JP 2008501701A5 JP 2007515574 A JP2007515574 A JP 2007515574A JP 2007515574 A JP2007515574 A JP 2007515574A JP 2008501701 A5 JP2008501701 A5 JP 2008501701A5
Authority
JP
Japan
Prior art keywords
annexin
agent
derivative
imaging
agent component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515574A
Other languages
English (en)
Japanese (ja)
Other versions
JP5139058B2 (ja
JP2008501701A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019399 external-priority patent/WO2005117848A2/en
Publication of JP2008501701A publication Critical patent/JP2008501701A/ja
Publication of JP2008501701A5 publication Critical patent/JP2008501701A5/ja
Application granted granted Critical
Publication of JP5139058B2 publication Critical patent/JP5139058B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515574A 2004-06-02 2005-06-02 新形成または新生脈管構造の検出、画像化および処置のための血管標的 Expired - Fee Related JP5139058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57611604P 2004-06-02 2004-06-02
US60/576,116 2004-06-02
PCT/US2005/019399 WO2005117848A2 (en) 2004-06-02 2005-06-02 Vascular targets for detecting, imaging and treating neoplasia or neovasculature

Publications (3)

Publication Number Publication Date
JP2008501701A JP2008501701A (ja) 2008-01-24
JP2008501701A5 true JP2008501701A5 (enExample) 2008-07-17
JP5139058B2 JP5139058B2 (ja) 2013-02-06

Family

ID=35463318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515574A Expired - Fee Related JP5139058B2 (ja) 2004-06-02 2005-06-02 新形成または新生脈管構造の検出、画像化および処置のための血管標的

Country Status (7)

Country Link
US (2) US20060024315A1 (enExample)
EP (1) EP1755646A2 (enExample)
JP (1) JP5139058B2 (enExample)
AU (1) AU2005249541B2 (enExample)
CA (1) CA2572451C (enExample)
TW (1) TWI445525B (enExample)
WO (1) WO2005117848A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
DK1960790T3 (en) * 2005-12-12 2017-03-06 Mosamedix Bv ANNEXIN DERIVATIVES SUITABLE FOR PREGNANCY FOR TREATMENT AND DIAGNOSIS
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2010061288A2 (en) * 2008-11-30 2010-06-03 University Of Witwatersrand, Johannesburg Polymeric pharmaceutical dosage form
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
TWI387750B (zh) * 2009-02-10 2013-03-01 Nat Defense Medical Ct Biomarker and detection method for detecting kidney disease
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
WO2012051556A1 (en) * 2010-10-15 2012-04-19 Duke University Compositions and methods for the treatment of cardiac surgery-associated acute kidney injury with annexin a1 peptide
WO2012135592A2 (en) * 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
CN102898527B (zh) * 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US11795197B2 (en) 2017-06-07 2023-10-24 Cedars-Sinai Medical Center Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
GB202019109D0 (en) * 2020-12-03 2021-01-20 Novai Ltd Marker for use in identifying or predicting angiogenesis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US20040115128A1 (en) 1995-09-08 2004-06-17 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
CA2228604A1 (en) 1995-09-08 1997-03-13 Jan E. Schnitzer Isolation of microdomains of caveolae and gpi-anchored proteins
US20030008819A1 (en) 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
WO1998053852A1 (en) 1997-05-30 1998-12-03 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
AU9477398A (en) 1997-09-10 1999-03-29 Burnham Institute, The Methods of identifying molecules that home to angiogenic vasculature in tumors
CA2219299A1 (en) * 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
WO2000052467A1 (en) 1999-03-02 2000-09-08 The University Of Dundee Methods of determining altered ndpk functions
HK1043314A1 (zh) 1999-06-17 2002-09-13 Regeneron Pharmaceuticals, Inc. 成像和导向肿瘤脉管系统的方法
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
DE10017249A1 (de) * 2000-04-06 2001-10-11 Peter Solisch In-Vitro-Verfahren zur Feststellung bösartiger Tumore in der Human- und Veterinärmedizin
AU2002211649A1 (en) 2000-10-11 2002-04-22 Targesome, Inc. Targeted therapeutic agents
WO2002030456A1 (en) * 2000-10-12 2002-04-18 The University Of Tennessee Research Corporation Targeting drug/gene carriers to irradiated tissue
AU2002306821A1 (en) 2001-03-22 2002-10-08 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US7666391B2 (en) * 2001-06-01 2010-02-23 Burnham Institute For Medical Research Breast homing peptides and methods of identifying same using aminopeptidase P
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US6531655B2 (en) * 2001-06-27 2003-03-11 Stuete Schaltgerate Gmbh & Co. Kg Protective-door handle
US20030162706A1 (en) * 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
EP1646357A4 (en) 2003-06-27 2007-01-10 Diadexus Inc PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
EP1670510A1 (en) * 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005117999A2 (en) * 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface

Similar Documents

Publication Publication Date Title
US11964021B2 (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
Cheng et al. Analytical measurement of PEGylated molecules
Bobo et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date: Bobo et al.
Jeon et al. Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity
JP5717256B2 (ja) ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防
Ko et al. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins
Agemy et al. Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32
JP6486004B2 (ja) 疎水性修飾ペプチドおよび肝臓特異的標的化のためのその使用
JP2005523687A5 (enExample)
JP2012100677A5 (enExample)
JP2007511463A5 (enExample)
Stucke-Ring et al. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
US20150174273A1 (en) Imaging and therapeutic methods for treating parathyroid tumors
Lin et al. Enhancement effect of a variable topology of a membrane-tethered anti-poly (ethylene glycol) antibody on the sensitivity for quantifying PEG and PEGylated molecules
López-Estévez et al. Biodistribution of 89Zr-Radiolabeled Nanoassemblies for Monoclonal Antibody Delivery Revealed through In Vivo PET Imaging
Jin et al. Immobilization of plasmid DNA on an anti‐DNA antibody modified coronary stent for intravascular site‐specific gene therapy
WO2014130454A1 (en) Non-covalent loading of plant picornavirus particles
Takahashi et al. Modern biomedical applications of magnetic nanoparticles
WO2016150521A1 (en) Functionalised magnetic nanoparticle
Li et al. Cell-Mimicking Nanodecoys Protect Lung Cells by Neutralization of SARS-CoV-2 Spike Proteins
Zheng et al. Peptide-/protein-mediated nano-bio interface and its applications
JP2019214530A (ja) 抗体修飾剤、抗体−抗体修飾剤複合体、抗体結合性担体、及び抗体の精製方法
JP2025504375A5 (enExample)
WO2020008404A1 (en) Chemical entities suitable for therapy having prolonged residence time in the circulation
Lodeiro et al. Bioinspired Functionalized Nanoparticles as Tools for Detection, Quantification and Targeting of Biomolecules